INSIGHTS ON DRUG DEVELOPMENT
-
![GettyImages-1388184871-quality-compliance-approval]( "Immuno-Oncology Biomarker Measurement With High Sensitivity And Speed")
Immuno-Oncology Biomarker Measurement With High Sensitivity And SpeedExplore results demonstrating the successful use of innovative ELISA assays to detect three key biomarkers: Programmed Death Ligand 1 (PD-L1), Interleukin-8 (IL-8), and Interferon Gamma (IFN-γ).
-
![organ chip porfolio thumb]( "Explore The Emulate Organ-Chip Portfolio")
Explore The Emulate Organ-Chip PortfolioUncover how these state-of-the-art Organ-Chip technologies can elevate your research and provide deeper insights into human physiology and therapeutic responses.
-
![GettyImages-2158441715-titration-analysis-scientist-flask-analysis]( "The Importance Of Reliable Mixing In ITC Experiments")
The Importance Of Reliable Mixing In ITC ExperimentsExplore how Isothermal Titration Calorimetry (ITC) precisely analyzes molecular interactions, which provides crucial thermodynamic data to understand physiological processes and develop new therapeutic strategies.
-
![mRNA GettyImages-1428646288]( "Advanced Therapies Going Mainstream: Are We There Yet?")
Advanced Therapies Going Mainstream: Are We There Yet?Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.
-
Eliminate Risk From Your Viral Vector Tech Transfers12/5/2025
Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.
-
Overcoming API Constraints And Tight Timelines With On-Demand Manufacturing3/20/2026
Use innovative lipid-based formulations and on-demand manufacturing to accelerate Phase 1 trials, enable flexible dose escalation, and maximize limited API for poorly soluble compounds.
-
Overcoming Excipient Risks And Challenges For Parenteral Formulations8/27/2025
Excipients are essential to parenteral formulations, which help protect APIs, enhance stability, and ensure safety. Learn how strategic excipient selection can optimize drug performance and patient outcomes.
-
Nanomedicine Modalities Find Path To Clinic Through Analytics5/16/2025
Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
Use Of Spray Drying In Pharmaceutical Product Development10/21/2024
Through this detailed exploration, participants will gain valuable knowledge on how to leverage spray drying to optimize drug development and delivery.
DRUG DEVELOPMENT SOLUTIONS
-
![M165 C]( "Encoded Stereo Microscopes - Reproduce Images In Minutes")
Encoded stereo microscopes Leica M165 C - Total recall of your settings
Your goal: high-quality images that allow measurements and can be accurately repeated with minimal effort. The Leica coded stereo microscopes help you to pave the way to correct results.
-
Coded microscopes consistently deliver calibrated and comparable images
-
Reproduce images in moments with the Leica “Store and Recall” function
-
Fully apochromatic corrected zoom optics deliver high quality images
-
Customize the microscope system to your task with the exclusive range of accessories
-
-
Enhance your research and obtain exceptional imaging and analysis with a configurable and upgradeable high-content screening system that captures high-definition images and robust data from 2D and 3D assays.
-
![scientists chemists laboratory-GettyImages-1055312560]( "Accelerate Molecules Through Development With Translational Pharmaceutics®")
By leveraging real-time data and operational efficiency, we accelerate timelines — manufacturing and releasing drug products in under seven days and reducing development cycles by up to 12 months.
-
![flow-chemistry-GettyImages-1403976499]( "Flow Process Technology")
Discover how integrated synthetic biology, advanced enzyme engineering, and global infrastructure accelerate biologic innovation through more efficient discovery, optimization, and development workflows.
-
![Female researcher analyzing scientific samples-GettyImages-2231025177]( "Curia R&D Pipeline Overview")
This pipeline outlines a sequence of late‑stage and emerging therapeutics projected to launch between 2024 and 2031, spanning immunology, neurology, psychiatry, rare disease, oncology, and inflammatory disorders.
